14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
TAK vs NBIX: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
NBIX Overall Winner
6-Pillar Tally: TAK 3 – 3 NBIX
Matrix Metrics: TAK 5 – 5 NBIX
As of Nov 16, 2026, Neurocrine Biosciences Inc (NBIX) is the stronger overall head-to-head candidate over Takeda Pharmaceutical Company Limited (TAK) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). TAK carries a Unified Composite Score of 47.7/100 (HOLD) at $21.61 (12.7x Forward P/E, 16.6% operating margin), whereas NBIX carries 31.4/100 (SELL) at $165.34 (13.6x Forward P/E, 26.6% operating margin).
Composite vs. Pillar Nuance: While TAK currently prints a higher short-term Unified Composite Score (47.7/100 HOLD vs. NBIX 31.4/100 SELL), NBIX captures the overall institutional head-to-head verdict (5–5 matrix metrics and 3–3 across the 6 pillars) due to superior fundamental profitability (26.6% vs. 16.6% operating margin) and revenue trajectory (+41.2% vs. +6.7% YoY).
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on TAK vs NBIX. Trailing 12-month operating profitability (TAK 16.6% vs NBIX 26.6%) and valuation multiples (TAK 12.7x vs NBIX 13.6x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Drug Manufacturers - Specialty & Generic value chain with $17.1B market capitalization and 26.6% operating margin.
OpEx & R&D Reinvestment38.1% of Rev ($1.41B)
90D Engineering Disclosures0 Published
Investor FAQ TAK vs NBIX Key Questions & Quantitative Answers
As of Nov 16, 2026, Neurocrine Biosciences Inc (NBIX) is the stronger overall head-to-head candidate over Takeda Pharmaceutical Company Limited (TAK) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). TAK carries a Unified Composite Score of 47.7/100 (HOLD) at $21.61 (12.7x Forward P/E, 16.6% operating margin), whereas NBIX carries 31.4/100 (SELL) at $165.34 (13.6x Forward P/E, 26.6% operating margin). Composite vs. Pillar Nuance: While TAK currently prints a higher short-term Unified Composite Score (47.7/100 HOLD vs. NBIX 31.4/100 SELL), NBIX captures the overall institutional head-to-head verdict (5–5 matrix metrics and 3–3 across the 6 pillars) due to superior fundamental profitability (26.6% vs. 16.6% operating margin) and revenue trajectory (+41.2% vs. +6.7% YoY).
NBIX leads the Growth & Scale pillar: TAK posts +6.7% YoY revenue growth and -9.8% YoY earnings growth on $25.7B TTM revenue (64.8% gross margin, 16.6% operating margin), compared with NBIX at +41.2% YoY revenue growth and -3.9% YoY earnings growth on $3.70B TTM revenue (64.7% gross margin, 26.6% operating margin). On trailing 12-month operating scale, TAK generates $25.7B in USD-normalized revenue versus $3.70B for NBIX. In operating R&D and SG&A reinvestment, TAK deploys 48.2% of Rev ($12.4B) (0 90-day corporate R&D disclosures) versus 38.1% of Rev ($1.41B) (0 disclosures) for NBIX.
TAK screens cheaper on headline valuation multiples. TAK trades at 12.7x Forward P/E, N/M Trailing P/E, 0.47x PEG, and 2.6x EV/Revenue (29.1% EBITDA margin), whereas NBIX trades at 13.6x Forward P/E, 25.1x Trailing P/E, 0.34x PEG, and 4.6x EV/Revenue (28.1% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against TAK (0.6% ROE) versus NBIX (20.4% ROE) capital efficiency.
In options market volatility and institutional positioning, TAK carries 22.4% implied volatility (5th %ile, Compressed (<25th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.02β · 22% Vol realized risk). By comparison, NBIX carries 32.0% implied volatility (22nd %ile, Compressed (<25th %ile)), a 0.24x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.60β · 54% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.